LUX Infusion Acquires Infuse IQ to Expand Network

LUX Infusion has significantly expanded its national footprint in the ambulatory infusion sector through the strategic acquisition of Infuse IQ. This move solidifies LUX Infusion's commitment to building a comprehensive, nationwide platform that integrates both ambulatory and home-based infusion services, catering to a growing demand for accessible and specialized medical treatments.

The integration of Infuse IQ, a provider operating six clinic locations and serving over ten distinct medical specialties, is expected to enhance patient access to LUX Infusion's established network. Referring physicians will benefit from augmented clinical support, accelerated therapy initiation timelines, streamlined insurance navigation, and improved data exchange capabilities, all crucial elements in optimizing patient care pathways within the complex healthcare ecosystem.

This transaction aligns with LUX Infusion's overarching omnichannel strategy, which aims to seamlessly blend the convenience of home infusion with the specialized care offered at ambulatory centers. The company's expanding operational reach now stretches across diverse regions, from the northern reaches of Alaska to the southeastern United States, with further market penetration anticipated.

The ambulatory infusion market is experiencing robust growth, driven by an aging population requiring chronic disease management and the increasing preference for outpatient care settings over traditional hospital stays. Industry reports indicate a compound annual growth rate exceeding 8% for this segment, underscoring the strategic importance of network expansion and service diversification for key players like LUX Infusion.

Ted Kramm, CEO of LUX Infusion, emphasized the deliberate nature of the acquisition, stating, “This acquisition is a reflection of our strategy to grow with purpose, partnering with organizations that share our values and raise the standard of care for patients who depend on infusion therapy. Infuse IQ has demonstrated exactly the kind of clinical excellence and patient-first culture that defines LUX Infusion.”

Echoing this sentiment, Brian Zweben, CEO of Infuse IQ, expressed enthusiasm for the future, noting, “Joining LUX Infusion marks an exciting new chapter for Infuse IQ and, most importantly, for the patients and providers we serve. LUX Infusion’s clinician-led approach, investment in technology, and deep commitment to the patient experience align with everything we have worked to build.” This synergy is anticipated to drive operational efficiencies and elevate the standard of patient-centric care across the combined entity.